Finding legitimacy for the role of budget impact in drug reimbursement decisions

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 1, 2009, Pages 49-55

  Niezen, Maartje G H ^d   De Bont, Antoinette ^a   Busschbach, Jan J V ^b,c   Cohen, Joshua P ^d   Stolk, Elly A ^b  

^a Erasmus University Rotterdam   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Viersprong Institute for Studies on Personality Disorders VISPD   (Netherlands)

^d Erasmus MC Rotterdam ^*

Author keywords

Budget impact; Healthcare rationing; Pharmaceutical policy; The Netherlands

Indexed keywords

BUDGET IMPACT; EQUAL OPPORTUNITY; HEALTHCARE RATIONING; LITERATURE REVIEWS; LOSS AVERSION; NETHERLANDS; OPPORTUNITY COSTS; PHARMACEUTICAL POLICY; POLICY MAKERS; SEMI STRUCTURED INTERVIEWS; THE NETHERLANDS; THEORETICAL FOUNDATIONS;

HEALTH CARE;

BUDGET CONTROL;

ARTICLE; AVERSION; BUDGET; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE POLICY; MEDICAL DECISION MAKING; NETHERLANDS; REIMBURSEMENT; SEMI STRUCTURED INTERVIEW; UNCERTAINTY; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HEALTH CARE PLANNING; HUMAN; RESOURCE ALLOCATION;

PRESCRIPTION DRUG;

BUDGETS; COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE REFORM; HEALTH POLICY; HEALTH RESOURCES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NETHERLANDS; PRESCRIPTION DRUGS; RESOURCE ALLOCATION;

EID: 60749105503     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309090072     Document Type: Article

References (43)

1. Al MJ, Feenstra TL, Hout BA. Optimal allocation of resources over health care programmes: Dealingwith decreasingmarginal utility and uncertainty. Health Econ. 2005;14:655-667.
2. Amerongen L. Crisis on clopidogrel. [in Dutch: Crisis over clopidogrel] Med Contact (Bussum). 2003:58.
3. Anand P. QALYs and the integration of claims in health-care rationing. Health Care Anal. 1999;7:239-253. (Pubitemid 29529742)
4. Bal R, Van de Lindeloof A. Public participation in benefit package decisions. Learning from experiences abroad. [in Dutch: Publieksparticipatie bij pakketbeslissingen. Leren van buitenlandse ervaringen]. Rotterdam: Instituut Beleid en Management Gezondheidszorg; 2005.
5. Berg M, Van Der Grinten T, Klazinga N. Technology assessment, priority setting and appropriate care in Dutch health care. Int J Technol Assess Health Care. 2004;20:35-43. (Pubitemid 38656959)
6. Birch S, Gafni A. Information created to evade reality (ICER): Things we should not look to for answers. Pharmacoeconomics. 2006;24:1121-1131. (Pubitemid 44683368)
7. Borstkankervereniging Nederland. Report undertreatment of breast cancer patients with metastatic HER2-positive tumours [in Dutch: Rapport onderbehandeling van borstkankerpatienten met uitgezaaide HER2-positieve tumoren]. Utrecht: Borstkankervereniging Nederland; 2005.
8. Braat D, Van Rijen O, Ottes L. Sensible and durable care. [in Dutch: Zinnige en duurzame zorg]. Nieuwsbrief Ned Vereniging Bio-ethiek. 2007:14;3-5.
9. Briggs A, Gray A. Using cost-effectiveness information. BMJ. 2000;320:246.
10. Cohen J, Stolk EA, Niezen MGH. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics. 2007;25:727-734. (Pubitemid 47481638)
11. Cohen JP, Stolk EA, Niezen MGH. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law. 2008;33:225-247.
12. Dakin HA, Devlin NJ, Odeyemi IA. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making. Health Policy. 2006;77:352-367.
13. Drummond M, Jonsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy. 1997;40:199-215. (Pubitemid 27285992)
14. Dupont D, Lee SL. The endowment effect, status quo bias and loss aversion: Rational alternative explanation. J Risk Uncertain. 2002;25:87-101. (Pubitemid 37131152)
15. Eijgelshoven M, Wieringa N, Van Der Vaart R, et al. Clopidogel: Evaluation of its use and the additional conditions. [in Dutch: Clopidogrel: Evaluatie van de inzet en de nadere voorwaarden]. Amstelveen: College voor Zorgverzekeringen; 2003.
16. Fox DM, Oxman AD, eds. Informing judgment: Case studies of health policy and research in six countries. New York: Milbank Memorial Fund; 2001.
17. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): The silence of the lambda. Soc Sci Med. 2006;62: 2091-2100.
18. Gafni A. Walter SD, Birch S, et al. An opportunity cost approach to sample size calculation in cost-effectiveness analysis. Health Econ. 2008;17:99-107. (Pubitemid 351227529)
19. Green J, Thorogood N. Qualitative methods for health research. London: SAGE; 2004.
20. Ham C, Coulter A. Explicit and implicit rationing: Taking responsibility and avoiding blame for health care choices. J Health Serv Res Policy. 2001;6:163-169. (Pubitemid 32607104)
21. Harris A, Buxton M, O'Brien B, et al. Using economic evidence in reimbursement decisions for health technologies. Expert Rev Pharmacoeconomics Outcomes Res. 2001;1:7-12.
22. Harris J. Cost-effectiveness and resource allocation. Reply to Dr. Cohen. JAMA. 2007;295:2723-2724.
23. Hoedemaekers R, Oortwijn W. Problematic notions in Dutch Health Care package decisions. Health Care Anal. 2003;11:287-294 (Pubitemid 38112586)
24. Kahneman D, Tversky A. Prospect theory: An analysis of decision under risk. Econometrica. 1979;47:263-291.
25. Mauskopf J. Budget impact analysis: Review of the state of the art. Expert Rev Pharmacoeconomics Outcomes Res. 2005;5:65-79. (Pubitemid 40590125)
26. Mauskopf J, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: Report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health. 2007;10:336-347. (Pubitemid 47481105)
27. Mauskopf J. Prevalence-based economic evaluation. Value Health. 1998;1:251-259.
28. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: Should we value rarity? BMJ. 2005;331;1016-1019 (Pubitemid 41552456)
29. Ministerie van Volksgezondheid, Welzijn en.Sport. IVF back in the benefit package. [in Dutch: IVF komt weer in basispakket.] Nieuwsbericht Den Haag; 2006.
30. Neumann PJ. Commentary on the ISPOR Task Force Report on budget impact analyses. Boston: Center for the Evaluation of Value and Risk in Health; 2007.
31. Niezen MGH, De Bont A, Stolk EA, et al. Conditional reimbursement within the Dutch drug policy. Health Policy. 2007;84:39-50.
32. Niezen-van der Zwet MGH, Stolk EA, Eijck A, et al. Evaluation of Schedule 2 as a policy instrument. [in Dutch: Evaluatie van Bijlage 2 als beleidsinstrument]. Rotterdam: Instituut Beleid en Management Gezondheidszorg / Erasmus MC; 2004.
33. Niezen MGH, Stolk EA, Uyl-de Groot CA, et al. Inequalities in oncology care: Economic consequences of high cost drugs. Eur J Cancer. 2007;42:2887-2892.
34. Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health. 2004;7:1-10. (Pubitemid 38186279)
35. Sendi P, Gafni A, Birch S. Ethical economics and costeffectiveness analysis: Is it ethical to ignore opportunity costs? Expert Rev Pharmacoeconomics Outcomes Res. 2005;5:661-665. (Pubitemid 43055857)
36. Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ. 2002;11:23-31. (Pubitemid 34097619)
37. Sendi P, Al MJ, Rutten FF. Portfolio theory and costeffectiveness analysis: A further discussion. Value Health. 2004;7:595-601. (Pubitemid 39390839)
38. Sendi PP, Briggs AH. Affordability and cost-effectiveness: Decision-making on the cost-effectiveness plane. Health Econ. 2001;10:675-680.
39. Stolk EA, Brouwer WB, Busschbach JJ. Rationalising rationing: Economic and other considerations in the debate about funding of Viagra. Health Policy. 2002;59:53-63.
40. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics. 2001;19:609-621. (Pubitemid 32531836)
41. Ubel PA, DeKay ML, Baron J, et al. Cost-effectiveness analysis in a setting of budget constraints-is it equitable? N Engl J Med. 1996;334:1174-1177. (Pubitemid 26137978)
42. Van Luijn JCF. CFH-rapport 99/05 Clopidogrel (Plavix) Ferrioxidesaccharaat (Venofer) Lactulose Granulaat (Legendal). Amstelveen; CVZ: 1999.
43. Van Oostenbruggen MF, Jansen RB, Mur K, et al. Penny and pound wise: Pharmacoeconomics from a governmental perspective. Pharmacoeconomics. 2005;23:219-226. (Pubitemid 40663629)